The FDA has approved sotatercept-csrk, the first activin signaling inhibitor therapy, for the management of patients with pulmonary arterial hypertension (PAH). Based on the Phase 3 STELLAR trial,...
Martha Kingman, FNP-C, DNP, and Bradley A. Maron, MD, review the latest guidelines and best practices for the primary care provider in the diagnosis and management of pulmonary arterial hypertension and...
Pulmonary arterial capacitance is a strong predictor of clinical outcomes for patients with pulmonary hypertension. The researchers assessed whether an echocardiographic surrogate for pulmonary arterial...
In a recent study, researchers sought to examine the relationship between smoking, nutritional status, and renal function in patients with arterial hypertension.
A new study highlights the effects of normobaric hypoxia on exercise performance among patients with pulmonary hypertension. Lead author Silvia Ulrich, MD, answered our questions about her team’s study. ...
It is unclear whether body size is linked to clinical and hemodynamic characteristics in PAH. In turn, researchers evaluated the relationship between body mass index, exercise capacity, and hemodynamics...
Current guidelines do not provide definitive recommendations for the use of oral prostacyclin pathway agents among patients with pulmonary arterial hypertension. In turn, an expert panel developed consensus...
It is unclear whether improving respiratory muscle function can increase exercise capacity among patients with pulmonary arterial hypertension. In turn, researchers evaluated the effects of inspiratory...
Previous studies have demonstrated that triple upfront combination therapy is an effective treatment for patients with severe pulmonary arterial hypertension. But what is the therapy’s impact on right...
